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Introduction. Acute myocardial infarction (AMI) is characterized by an intense inflammatory response in which Interleukin-1 (IL-1) plays a central 
role. We designed and conducted a randomized double-blind placebo-controlled pilot trial using a recombinant IL-1 receptor antagonist, anakinra, 
to test the hypothesis that IL-1 blockade would lead to more favorable LV remodeling in patients with STEMI.
Methods:  Ten patients with reperfused STEMI were randomized within 24 hours to anakinra 100 mg subcutaneously daily for 14 days or matching 
placebo. Serial cardiac magnetic resonance (CMR) imaging was performed 24-96 hours from admission and at follow up (10-14 weeks). The primary 
endpoint was the difference in the interval change in LV end-systolic volume index (LVESVi) between groups.
Results:  There was a +2.0 mL/m2 (+1.0/+11.5) increase in LVESVi by CMR in the placebo group and a -3.2 mL/m2 (-4.5/-1.6) decrease in the 
anakinra group (p=0.033), with a median difference of 5.2 mL/m2. Similar differences were observed in the LV end-diastolic volume index (median 
difference of 7.6 mL/m2, p=0.033). The change in CRP levels between admission and 72 hours correlated with the change in LVESVi (R=+0.71, 
p=0.022) by CMR.
Conclusions:  In this pilot study of patients with STEMI IL-1 blockade favorably affected LV remodeling and 
thus reducing IL-1 activity may represent a new therapeutic strategy to prevent heart failure following AMI
